|
|
|
Genzyme Lowers Target, JDA Cuts Sales Outlook |
| |
Author: Irina Uzunova
123jump.com
Email article | Print
article
Genzyme lowers its full-year guidance as soft demand and high inventory levels of its kidney drug Renagel continue to hurt sales. JDA Software cuts software license sales outlook. |
|
| |
|
|
More: